ATLAS: Asian clinical TriaLs network for c Ancer S

ASIA'S LEADING PLATFORM FOR CANCER TREATMENT

3 Key Benefits of ATLAS

01 Leading Institutions & KOLs

- Featuring 40+ local leading centers and 100+ top oncology experts
- Robust and sustainable research excellence through specialized expertise

02 Academia –Regulatory –Industry Collaboration

- Optimized development predictability through cross -sector alliance
- Ongoing dialogue among industry, academia and government

03 Quality/Speed/Cost

- Enhanced Trial Quality
- Accelerated Enrollment
- Cost Efficiency

ATLAS
ASIAN CLINICAL TRIALS NETWORK FOR CANCERS PROJECT

Goals of ATLAS

- Establish the robust network for clinical trials in Asia
- Introduce genome-based medicine in Asian
- Obtain/expand drug indication in Asia promoting regulatory harmonization with PMDA

10 Countries/Regions

40 Sites

ATLAS project was launched in 2020 by National Cancer Center Hospital Japan with government funding support.

For more details: ncch_itm_office@ml.res.ncc.go.jp

ACADEMIA –REGULATORY–INDUSTRY COLLABORATION



Leverages group strength for enhanced multi -country trials

Drive system optimization for industry -wide benefit

Asian regulatory harmonization through communication with local regulators

ATLAS AS A CLINICAL TRIAL GROUP

SHARED DECISION MAKING WITH NATIONAL PRINCIPAL INVESTIGATORS

ATLAS Board

25 Members

governs all strategic decisions and operations

President
Kan Yonemori
(Japan)

President elect
Darren Lim Wan Teck
(Singapore)

Project Director
Kenichi Nakamura
(Japan)



ATLAS Study Group

36 Members **3+** Groups

Specialized cancer -type groups maintain high -level expertise in each field.

Head and Neck Cancer Group

Chair
Darren Lim Wan Teck (Singapore)

Secretary
Pei Jye Voon (Malaysia)

Sarcoma and Rare Cancer Group

Chair
Tom Wei-Wu Chen (Taiwan)

Secretary
Hitomi Okuma (Japan)

Hepato - pancreato - biliary Group, and more (in planning)

Maximizing ROI with Cost -Effective Clinical Trials in Asia

Optimized Management

Efficient project oversight under ATLAS HQ

- Optimized in -house trial management to lower CRO costs
- Feasibility assessments to optimize site selection
- Integrated data management and statistical analysis capabilities

Enhanced Trial Quality

- Comprehensive training programs, including onsite education, to enhance workforce expertise
- Robust data management aligned with regulatory submission requirements

Accelerated Enrollment

Expedited recruitment through high -volume centers across multiple countries

Example 1: Enrollment completed 6 months ahead (24 → 18 months)

Example 2: Expected completion 8 months early (24 → 16 months)

Cost Efficiency

- Cost reduction compared to the US and Europe
- Lower personnel costs
- Reduced diagnostic and procedural expenses
- Faster patient recruitment, improving cost efficiency